CLINICAL DOSE PREDICTION FOR CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPIES USING A MULTI-SCALE QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) PLATFORM MODEL.

被引：0
|
作者：
Paleja, B. [1 ]
Garai, S. [2 ]
Gangwar, V. [1 ]
Yadav, S. [1 ]
Nair, G. [1 ]
Chakravarthy, S. Pallikonda [1 ]
机构：
[1] Vantage Res, Chennai, Tamil Nadu, India
[2] Indian Inst Sci, Bengaluru, India
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-018
引用
收藏
页码：S52 / S53
页数：2
相关论文
共 50 条
  • [1] Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
    Ajeet Gajra
    Abigail Zalenski
    Aishwarya Sannareddy
    Yolaine Jeune-Smith
    Kandice Kapinos
    Ankit Kansagra
    Pharmaceutical Medicine, 2022, 36 : 163 - 171
  • [2] Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
    Gajra, Ajeet
    Zalenski, Abigail
    Sannareddy, Aishwarya
    Jeune-Smith, Yolaine
    Kapinos, Kandice
    Kansagra, Ankit
    PHARMACEUTICAL MEDICINE, 2022, 36 (03) : 163 - 171
  • [3] Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T-Cell Therapy
    Hardiansyah, Deni
    Ng, Chee Meng
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, 12 (04): : 343 - 349
  • [4] Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
    Giulia Bonaldo
    Nicola Montanaro
    Domenico AlbertoVaccheri
    European Journal of Clinical Pharmacology, 2021, 77 : 1225 - 1234
  • [5] Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
    Bonaldo, Giulia
    Montanaro, Nicola
    Vaccheri, Alberto
    Motola, Domenico
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (08) : 1225 - 1234
  • [6] Prediction of First-in-Human Dose of Chimeric Antigen Receptor-T (CAR-T) Cells from Mice
    Mahmood, Iftekhar
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2024, 49 (06) : 715 - 722
  • [7] Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications
    Thanindratarn, Pichaya
    Dean, Dylan C.
    Nelson, Scott D.
    Hornicek, Francis J.
    Duan, Zhenfeng
    CANCER TREATMENT REVIEWS, 2020, 82
  • [8] LITERATURE REVIEW ON TOTAL MEDICAL COSTS AND COST COMPONENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPIES
    Ma, Q.
    Kuzan, D.
    Zhang, J.
    VALUE IN HEALTH, 2019, 22 : S422 - S422
  • [9] Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
    Brammer, Jonathan E.
    Braunstein, Zachary
    Katapadi, Aashish
    Porter, Kyle
    Biersmith, Michael
    Guha, Avirup
    Vasu, Sumithira
    Yildiz, Vedat O.
    Smith, Sakima A.
    Buck, Benjamin
    Haddad, Devin
    Gumina, Richard
    William, Basem M.
    Penza, Sam
    Saad, Ayman
    Denlinger, Nathan
    Vallakati, Ajay
    Baliga, Ragavendra
    Benza, Raymond
    Binkley, Philip
    Wei, Lai
    Mocarski, Mason
    Devine, Steven M.
    Jaglowski, Samantha
    Addison, Daniel
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
  • [10] Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment
    Nenna, Antonio
    Carpenito, Myriam
    Chello, Camilla
    Nappi, Pierluigi
    Annibali, Ombretta
    Vincenzi, Bruno
    Grigioni, Francesco
    Chello, Massimo
    Nappi, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
12345